These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11930926)

  • 1. Combination drug approved to treat HIV.
    FDA Consum; 2001; 35(1):5. PubMed ID: 11930926
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral approved for use in infants.
    Am Fam Physician; 2001 Jun; 63(12):2469. PubMed ID: 11430459
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluvia tablet approved in 19 African countries.
    AIDS Patient Care STDS; 2007 Aug; 21(8):604-5. PubMed ID: 17902244
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA notifications. Kaletra revisions to packaging approved.
    AIDS Alert; 2010 Mar; 25(3):34. PubMed ID: 20629261
    [No Abstract]   [Full Text] [Related]  

  • 5. Expanded access program for ABT-378 under way.
    Slovick J
    Posit Living; 1999 Nov; 8(10):10. PubMed ID: 11367322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
    TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
    [No Abstract]   [Full Text] [Related]  

  • 7. Kaletra OK'd by FDA.
    James JS
    Posit Living; 2000 Nov; 9(9):8, 13. PubMed ID: 12154764
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-HIV agents. Kaletra and Meltrex update.
    TreatmentUpdate; 2005; 17(5):4-5. PubMed ID: 17225278
    [No Abstract]   [Full Text] [Related]  

  • 9. [After 3 years no resistance development. Protease inhibitor with staying power].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():56-7. PubMed ID: 12043076
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA notifications. HIV-1 adult treatment guidelines are updated.
    AIDS Alert; 2006 Jun; 21(6):71. PubMed ID: 16795141
    [No Abstract]   [Full Text] [Related]  

  • 11. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis coinfection and LPV/RTV.
    Carter M
    IAPAC Mon; 2004 Oct; 10(10):398. PubMed ID: 15801120
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug interactions. Coming soon--a new formulation of Kaletra.
    TreatmentUpdate; 2006; 18(3):7. PubMed ID: 17209241
    [No Abstract]   [Full Text] [Related]  

  • 14. The state of access to Kaletra.
    Huff B
    GMHC Treat Issues; 2006; 20(4-7):4-5. PubMed ID: 17228448
    [No Abstract]   [Full Text] [Related]  

  • 15. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA notifications. FDA approves half-strength Kaletra.
    AIDS Alert; 2008 Jan; 23(1):10. PubMed ID: 18572474
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug interactions. Kaletra and ezetimibe.
    TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
    AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.